|
Press Releases |
|
|
|
Friday, March 29, 2024 |
|
乐普生物2023年收入快速增长,亏损大幅收窄,ADC进入收获期 |
more info >> |
|
樂普生物2023年收入快速增長,虧損大幅收窄,ADC進入收穫期 |
more info >> |
|
Friday, August 25, 2023 |
|
乐普生物公布2023年中期业绩 |
聚焦于肿瘤治疗领域的创新型生物制药公司──乐普生物科技股份有限公司(「乐普生物」或「公司」,股份代号:2157.HK),于今日公布2023年中期业绩。 more info >> |
|
樂普生物公佈2023年中期業績 |
聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」,股份代號:2157.HK),於今日公佈2023年中期業績。 more info >> |
|
Friday, March 17, 2023 |
|
乐普生物公布2022年度业绩 |
聚焦于肿瘤治疗领域的创新型生物制药公司──乐普生物科技股份有限公司(「乐普生物」或「公司」,股份代号:2157.HK),于今日公布2022年度业绩。 more info >> |
|
樂普生物公佈2022年度業績 |
聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」,股份代號:2157.HK),於今日公佈2022年度業績。 more info >> |
|
Thursday, February 23, 2023 |
|
乐普生物和康诺亚共同宣布与阿斯利康就CMG901达成全球独家授权协议 |
乐普生物科技股份有限公司 (HK:02157)和康诺亚生物医药科技有限公司(HK:02162)今日共同宣布与阿斯利康(AstraZeneca,LSE/STO/纳斯达克:AZN)就潜在世界首创Claudin 18.2抗体偶联药物CMG901达成全球独家授权协议。 more info >> |
|
樂普生物和康諾亞共同宣佈與阿斯利康就CMG901達成全球獨家授權協定 |
樂普生物科技股份有限公司 (HK:02157)和康諾亞生物醫藥科技有限公司(HK:02162)今日共同宣佈與阿斯利康(AstraZeneca,LSE/STO/納斯達克:AZN)就潛在世界首創Claudin 18.2抗體偶聯藥物CMG901達成全球獨家授權協定。 more info >> |
|
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901 |
On 23 February, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). more info >> |
|
Thursday, September 29, 2022 |
|
乐普生物PD-1单抗普佑恒(TM)获批新适应症,MRG003获CDE纳入突破性治疗药物名单 |
乐普生物科技股份有限公司 (「乐普生物」或「公司」,股份代号:2157.HK) 宣布,公司旗下首款创新型生物药抗PD-1抗体——普佑恒™(通用名:普特利单抗注射液)已获得国家药品监督管理局(NMPA)批准上市销售。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Shaping the Future of Technology with AI Everywhere Take Center Stage at the 13th Big CIO Show
May 10, 2024 20:55 HKT/SGT
|
|
|
DOCOMO to Launch "NTT DOCOMO GLOBAL" for Global Expansion
May 10, 2024 18:13 JST
|
|
|
Japan Energy Summit and Exhibition Hosts and Sponsors Demonstrate the Importance of Accelerating Decarbonisation
May 10, 2024 16:04 HKT/SGT
|
|
|
Pertamina International Shipping (PIS) Welcomes 2 VLGC Tankers to Its Fleet, Takes Top-Tier Position in ASEAN LPG Transport
May 10, 2024 16:00 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2024 Winter Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
May 10, 2024 15:09 HKT/SGT
|
|
|
三菱重工など、電力系統の混雑緩和を実現するシステムのフィールド実証を開始
May 10, 2024 11:50: JST
|
|
|
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
|
|
|
InfoComm Asia 2024 "Asia's International Pro AV Exhibition" Returns to Thailand
May 10, 2024 10:30 HKT/SGT
|
|
|
BLUETTI Unlocks Special Mother's Day Offerings, Perfect Gift Ideas for Moms
May 10, 2024 10:00 HKT/SGT
|
|
|
AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:33 HKT/SGT
|
|
|
SSR MINING (SSRM) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies SSR Mining Investors of a Class Action Lawsuit and May 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:26 HKT/SGT
|
|
|
CHEMOURS (NYSE: CC) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:20 HKT/SGT
|
|
|
DOXIMITY (NYSE: DOCS) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and June 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:13 HKT/SGT
|
|
|
特步宣布战略性出售K-Swiss及帕拉丁 并优化财务结构
May 9, 2024 20:28 HKT/SGT
|
|
|
特步宣佈戰略性出售K-Swiss及帕拉丁 並優化財務結構
May 9, 2024 20:25 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|